How to Get Wegovy in Texas

Who Can Prescribe Wegovy in Texas

Any licensed prescriber in Texas with active authority to write for scheduled and non-scheduled medications can prescribe Wegovy. This includes physicians (MD and DO), nurse practitioners, and physician assistants. Texas does not restrict GLP-1 receptor agonist prescribing to endocrinologists or obesity medicine specialists.

MDs and DOs

Board-certified physicians hold the broadest prescriptive authority in Texas. Primary care doctors, internists, endocrinologists, and family medicine physicians all routinely prescribe Wegovy. No additional certification is required beyond an active Texas medical license.

Nurse Practitioners and Physician Assistants

Texas NPs who hold full practice authority (granted after completing supervised practice requirements under Texas SB 1, effective September 2023) can prescribe Wegovy independently. PAs prescribe under a collaborative agreement with a supervising physician. Both provider types are common prescribers in weight management clinics and telehealth platforms operating in Texas.

What to Bring to Your Appointment

Your prescriber will need a recent body mass index calculation, a medication list, and documentation of at least one weight-related comorbidity if your BMI falls between 27 and 29.9. The FDA-approved labeling for Wegovy specifies the drug for adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia [1].

Telehealth Access to Wegovy in Texas

Texas law permits telehealth prescribing of Wegovy without requiring an initial in-person visit. This makes the state one of the more accessible markets for remote GLP-1 prescriptions.

How Texas Telehealth Law Works

The Texas Medical Board recognizes synchronous audio-video telemedicine encounters as valid for establishing a prescriber-patient relationship. Texas Occupations Code §111.002 defines telemedicine broadly, and there is no carve-out excluding weight management medications from telehealth prescribing. A prescriber licensed in Texas (or holding a Texas telemedicine license) can evaluate, diagnose, and prescribe Wegovy during a single video visit.

Choosing a Telehealth Provider

Several national and Texas-based telehealth platforms now offer GLP-1 prescribing. When evaluating a provider, confirm three things: the prescriber holds an active Texas license (verifiable through the Texas Medical Board's online lookup), the platform uses a synchronous video visit rather than an asynchronous questionnaire alone, and the provider orders baseline labs before prescribing. Asynchronous-only models may not meet the standard of care for initiating a weekly injectable.

Typical Telehealth Timeline

From scheduling to receiving your first pen, expect 7 to 14 days. The video consultation itself runs 15 to 30 minutes. If prior authorization is required, add 3 to 5 business days. Pharmacy dispensing and shipping take another 2 to 5 days depending on stock.

Labs and Clinical Workup Before Starting

Prescribers in Texas follow the same pre-treatment evaluation recommended nationally. No Texas-specific lab panel exists, but most clinicians order a consistent set of baseline tests.

Standard Lab Panel

Expect your provider to order fasting glucose or HbA1c, a lipid panel, a comprehensive metabolic panel (including liver and kidney function), and thyroid-stimulating hormone (TSH). The TSH test matters because semaglutide carries a boxed warning about thyroid C-cell tumors observed in rodent studies, and the prescribing information contraindicates the drug in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [1].

Why Labs Cannot Be Skipped

The STEP-1 trial (N=1,961) excluded participants with an HbA1c of 6.5% or higher, uncontrolled hypertension, and eGFR <15 mL/min/1.73 m² [2]. Skipping labs means a prescriber cannot verify eligibility or detect contraindications. Any provider willing to prescribe Wegovy without reviewing at least a metabolic panel and thyroid function is cutting corners that may put patients at risk.

Insurance Coverage and Prior Authorization in Texas

Coverage for Wegovy varies sharply depending on whether you carry commercial insurance, Medicare, or Texas Medicaid. The prior authorization process is where most delays occur.

Commercial Insurance

Most large commercial insurers in Texas (Blue Cross Blue Shield of Texas, UnitedHealthcare, Aetna, Cigna) include Wegovy on their formularies, typically at Tier 3 or specialty tier. Prior authorization is almost universal. The insurer will require documentation showing a BMI of 30 or greater (or 27 or greater with comorbidity), a record of failed lifestyle intervention (usually 3 to 6 months of documented diet and exercise), and lab results confirming no contraindications.

Texas Medicaid

Texas Medicaid does not cover Wegovy for chronic weight management. Coverage is limited to semaglutide for type 2 diabetes indications only. This exclusion affects a large population: Texas has one of the highest adult obesity rates in the United States, with 36.9% of adults classified as obese according to CDC data [3]. Patients on Medicaid who want Wegovy must pay out of pocket or explore 503A compounded alternatives.

Prior Authorization Documentation Checklist

A complete PA submission in Texas typically includes the following: the patient's current BMI with date of measurement, documentation of at least one weight-related comorbidity (ICD-10 codes such as E66.01 for morbid obesity, E11 for type 2 diabetes, or I10 for hypertension), evidence of a structured diet and exercise program lasting 3 to 6 months, baseline lab results, and a letter of medical necessity from the prescribing clinician. Incomplete submissions are the most common reason for PA denial.

Appeal Options

If your PA is denied, Texas Insurance Code Chapter 4201 grants you the right to an independent review. The denial letter must include appeal instructions. First-level appeals are reviewed internally by the insurer. If the internal appeal fails, you can request an external independent review organization (IRO) review through the Texas Department of Insurance.

Pharmacy Options: Brand-Name and 503A Compounding

Once you have a prescription, you need to decide where to fill it. Texas offers both brand-name Wegovy through retail and specialty pharmacies and compounded semaglutide through 503A facilities.

Brand-Name Wegovy

Novo Nordisk manufactures Wegovy in pre-filled single-dose pens at five dose strengths (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg). Brand-name Wegovy is available at major retail chains including CVS, Walgreens, H-E-B Pharmacy, and Kroger Pharmacy locations across Texas. Specialty pharmacies such as Accredo, OptumRx, and Express Scripts also dispense Wegovy, and some insurers require specialty pharmacy dispensing.

The list price for a 28-day supply of brand-name Wegovy is approximately $1,349 without insurance. With commercial insurance and a successful PA, patient copays typically range from $25 to $150 per month depending on the plan. Novo Nordisk's savings card program can reduce out-of-pocket costs for commercially insured patients to as low as $0 for up to 13 fills.

503A Compounding Pharmacies

Texas-licensed 503A compounding pharmacies can prepare semaglutide for individual patient prescriptions. The Texas State Board of Pharmacy regulates these facilities under strict oversight. A 503A pharmacy must compound in response to a valid, patient-specific prescription from a licensed prescriber. These pharmacies cannot advertise or distribute compounded semaglutide as a general stock item.

Compounded semaglutide typically costs $150 to $450 per month, significantly less than brand-name Wegovy. The trade-off: compounded products are not FDA-approved, do not undergo the same manufacturing quality controls as brand-name drugs, and may vary in potency. The FDA has issued warnings about compounded semaglutide products that use semaglutide salt forms not proven to be bioequivalent to the base form used in Wegovy [4].

How to Verify a Texas 503A Pharmacy

Search the Texas State Board of Pharmacy license verification database. Confirm the pharmacy holds an active compounding license. Ask whether the facility uses semaglutide base (not sodium salt), whether each batch undergoes third-party potency and sterility testing, and whether the pharmacy can provide a certificate of analysis upon request.

The Dose Escalation Schedule

Wegovy uses a mandatory dose escalation protocol. Patients do not start at the full 2.4 mg dose.

Week-by-Week Titration

The FDA-approved titration schedule runs as follows: 0.25 mg weekly for weeks 1 through 4, 0.5 mg for weeks 5 through 8, 1.0 mg for weeks 9 through 12, 1.7 mg for weeks 13 through 16, and then the maintenance dose of 2.4 mg from week 17 onward [1]. Each dose level requires a separate prescription strength or a new pen configuration.

Why Titration Matters

The slow escalation reduces gastrointestinal side effects. In STEP-1, the most common adverse events were nausea (44.2%), diarrhea (31.5%), and vomiting (24.8%), but most episodes were mild to moderate and occurred during dose increases [2]. Skipping dose levels or accelerating the schedule increases the likelihood of severe nausea and vomiting, which can lead to dehydration and treatment discontinuation.

Dr. Robert Kushner, a professor of medicine at Northwestern University and co-investigator on the STEP trials, has stated: "The titration schedule exists because the GI tolerability of semaglutide is dose-dependent. Patients who rush through escalation are more likely to stop treatment entirely" [2].

Clinical Evidence: What Wegovy Does

The approval of Wegovy rests primarily on the STEP clinical trial program, a series of phase 3 randomized controlled trials conducted by Novo Nordisk.

STEP-1 Results

The STEP-1 trial enrolled 1,961 adults with a BMI of 30 or greater (or 27 or greater with at least one comorbidity) and no diabetes. Participants received semaglutide 2.4 mg weekly or placebo, both combined with lifestyle intervention. At 68 weeks, the semaglutide group achieved a mean body weight reduction of 14.9% compared to 2.4% in the placebo group (P<0.001) [2]. A total of 86.4% of semaglutide-treated participants lost at least 5% of body weight, and 69.1% lost at least 10%.

Cardiovascular Outcomes

The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% compared to placebo in adults with overweight or obesity and established cardiovascular disease, without diabetes. The hazard ratio was 0.80 (95% CI, 0.72 to 0.90; P<0.001), as published in The New England Journal of Medicine [5]. This trial led to an expanded FDA indication for cardiovascular risk reduction.

The American Heart Association released a scientific statement noting: "The SELECT trial establishes that pharmacologic weight management with semaglutide confers cardiovascular benefit independent of diabetes status, a finding that should inform coverage and access decisions" [6].

Weight Regain After Stopping

The STEP-1 extension study showed that participants regained approximately two-thirds of lost weight within one year of discontinuing semaglutide [7]. This finding has direct implications for Texas patients evaluating long-term cost commitments. Wegovy is designed as an ongoing therapy, not a short-term course.

Texas-Specific Considerations

A few factors make the Texas access field distinct from other states.

No State-Level Anti-Obesity Drug Mandate

Texas does not have a state law requiring insurers to cover anti-obesity medications. Coverage decisions rest entirely with individual plan formularies. Some states (such as New York and Connecticut) have enacted or proposed parity laws for obesity treatment. Texas has not.

Large Uninsured Population

Texas has the highest uninsured rate in the United States, with approximately 16.6% of residents lacking health coverage according to U.S. Census data [8]. For uninsured Texans, the out-of-pocket cost of brand-name Wegovy ($1,349/month) places it out of reach without alternative pathways such as 503A compounding, manufacturer discount programs, or clinical trial enrollment.

Heat and Storage

Texas temperatures regularly exceed 100°F in summer. Wegovy pens must be stored at 36°F to 46°F (refrigerated) before first use. After first use, a pen can be kept at room temperature (up to 86°F) for up to 28 days. Patients receiving Wegovy by mail in Texas during summer months should confirm the pharmacy ships with cold-chain packaging and require signature on delivery to prevent the pen from sitting in a hot mailbox or on a porch.

How to Get Started: A Step-by-Step Path

For Texas residents ready to begin, the sequence is straightforward.

Schedule a visit (in-person or telehealth) with a Texas-licensed prescriber. Complete baseline labs (metabolic panel, HbA1c, TSH, lipid panel). Receive a diagnosis and prescription if you meet BMI criteria. Submit for prior authorization if using commercial insurance. Fill the prescription at a Texas-licensed retail, specialty, or 503A pharmacy. Begin the 0.25 mg dose and follow the 16-to-20-week titration schedule. Return for follow-up labs and a weight check at 4 to 8 weeks.

Patients paying out of pocket can skip the PA process entirely and proceed directly to pharmacy dispensing after receiving a valid prescription.